Coccidiosis vaccines
The present invention relates to coccidia strains and, in one embodiment, to microbiological cultures comprising such strains. In preferred embodiments, the coccidia strains are selected for tolerance to one group of coccidiostatic drugs, sensitivity to a second group of coccidiostatic drugs, and decreased proliferative capacity. Another embodiment of the invention relates to vaccines based on the coccidia strains according to the invention.
1. A coccidiosis vaccine comprising a pharmaceutically acceptable carrier; and occysts from at least one strain of Eimeria coccidia having:
a tolerance for at least one ionophoric drug,
a sensitivity to at least one DNA synthesis inhibitor drug, and
a decreased proliferative capacity,
and wherein the at least one strain Eimeria coccidia is selected from the group consisting of Eimeria acervulina strain ACA-99112612, Eimeria tenella strain ACT-99112611, and Eimeria maxima strain ACVM-99112610.
2. The coccidiosis vaccine according to claim 1 , further comprising antigenic material of at least one virus or other microorganism pathogenic to poultry.
3. The coccidiosis vaccine according to claim 2 , wherein said at least one virus or other microorganism is selected from the group consisting of Eimeria tenella, E. necatrix, E. maxima, E. brunette, E. acervulina, E. mitis and E. praecox , Infectious Bronchitis virus, Newcastle Disease virus, Infectious Bursal Disease, Chicken Anemia agent, Avian Reovirus, Mycoplasma gallisepticum , Turkey Rhinotracheitis virus, Hemophilus paragallinarum , Chicken Poxvirus, Avian Encephalomyelitisvirus, Fowl Cholera and E. coli.
4. A coccidiosis vaccine, comprising: a pharmaceutically acceptable carrier; and oocysts from at least two strains of Eimeria coccidia, said at least two strains of Eimeria coccidia being selected from the group consisting Eimeria acervulina strain ACA-99112612, Eimeria tenella strain ACT-99112611, and Eimeria maxima strain ACVM-99112610.